More number of diseases are covered where allogeneic (non self donor marrow) or blood stem cell transplantation (BMT) is being used as treatment.
It includes malignant hematological diseases such as leukemia, myelodysplastic syndrome, lymphomas and others. BMT is generally used for younger patients due to high incidence of treatment related morbidity and mortality.
There are several factors such as severity of co-morbidities, organ malfunction, overweight and other metabolic disorders are responsible for transplant related toxicity and mortality in ageing individuals. Analysis of the existing data indicates that the recipient's age above 50-55 years is associated with inferior outcome after myeloablative BMT. The developments of reduced intensity preparative regimens have revolutionized stem cell transplantation. Recent studies have shown that BMT is feasible and effective in patients over 70 years of age.
An autologous (self donor) bone marrow or stem cell transplant is practical into mid 60s. The upper age limit is getting expanded into the 70s, depending on factors such as disease, therapy and the general health of the patient.
A myeloablative allogeneic bone marrow or stem cell transplant is impractical in patients beyond their mid 50s due to the toxicity even though the upper age limit has expanded slightly.
In the case of non-myeloablative allogeneic, bone marrow or stem cell transplant is possible in patients who are in their 60s and 70s based on disease and donor source.
More Articles :